Search Orphan Drug Designations and Approvals
-
| Generic Name: | antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) antibody targeting tissue factor (TF) and YL0010014, a topoisomerase I inhibitor |
|---|---|
| Date Designated: | 11/17/2025 |
| Orphan Designation: | treatment of pancreatic cancer |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Evopoint Biosciences USA, Inc. 300 Baker Avenue, Suite 300 Concord, Massachusetts 01742 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







